生长激素被纳入医保，长春高新“现金牛”何以失速？

Core Viewpoint - Changchun High-tech's 2025 performance forecast indicates a significant decline in key financial metrics, with net profit expected to drop by 91.48%-94.19% compared to 2024, reflecting ongoing challenges in the company's operations [1][2]. Financial Performance - The company anticipates a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, a drastic decrease from 2.583 billion yuan in 2024 [1][2]. - The non-recurring net profit is projected to decline by 82.09%-84.56%, with basic earnings per share shrinking from 6.42 yuan to between 0.37 yuan and 0.55 yuan [1][2]. - For the first three quarters of 2024, the company reported a revenue of 9.807 billion yuan, down 5.60% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year, indicating worsening performance in the fourth quarter [2]. Business Challenges - The decline in performance is attributed to multiple pressures, including pricing adjustments in the growth hormone business following its inclusion in the medical insurance catalog, ongoing losses from subsidiary Baike Biology, and high costs associated with R&D and new product market cultivation [2][3]. - The growth hormone business, which is a key revenue driver, faces significant profit margin compression due to new pricing policies and increased competition from generic drug manufacturers [5][6]. Market Dynamics - The inclusion of long-acting growth hormone in the national medical insurance catalog is seen as a double-edged sword; while it expands patient access, it also necessitates price reductions that adversely affect profit margins [5][6]. - The competitive landscape has intensified, with the market no longer dominated by JinSai Pharmaceuticals, leading to increased pricing pressure and reduced profit contributions from the growth hormone segment [6][12]. Innovation and Strategic Initiatives - Despite short-term pressures, JinSai Pharmaceuticals is advancing its innovation and internationalization strategies, with multiple new product approvals and collaborations aimed at expanding market reach [3][8]. - The company has submitted an H-share listing application to the Hong Kong Stock Exchange, aiming to enhance financing channels and support its growth strategy [11]. - Significant R&D investments are being made, with R&D expenses reaching 1.733 billion yuan in the first three quarters of 2025, representing a 22.96% increase year-on-year [9][12]. Future Outlook - The successful commercialization of innovative products, such as JinBeiXin® and MeiShiYa®, which have been included in the medical insurance catalog, is expected to drive revenue growth and offset declines in traditional segments [9][12]. - The internationalization strategy, including partnerships and market expansion efforts, is anticipated to open new growth avenues and enhance the company's competitive position in the global market [11][12].